RNAC 株価分析 — CARTESIAN THERAPEUTICS INC. (Healthcare >> Biotechnology)
RNAC に関するよくある質問
RNACのPER(株価収益率)は?
CARTESIAN THERAPEUTICS INC.(RNAC)は現在PER 14.30倍で取引されています。
RNACのROE(自己資本利益率)は?
CARTESIAN THERAPEUTICS INC.のROEは102.47%です。
RNACの配当利回りは?
CARTESIAN THERAPEUTICS INC.の配当利回りは0.00%です。
RNACの品質スコア(Quality Score)は?
当社のAIはRNACの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
RNACは今が買い時ですか?
当社AIのタイミングスコアは100点中55点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
RNACはどのセクターに属しますか?
CARTESIAN THERAPEUTICS INC.はHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
RNAC AI Analysis Summary
Our AI summary for RNAC: CARTESIAN THERAPEUTICS INC. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 14.30, ROE of 102.47%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 7.80
Price
0.07
(0.91%)
Day Change
|
|
|---|
RNAC, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.80 |
| PBV / Sector |
-1.53 / 5.20
|
| Earning Per Share | -5.21 |
| PE / Sector |
14.30 / 19.97
|
| PEG or PE/Growth / Sector |
-0.07 / 1.22
|
| Average 1M Daily Value |
1.17 M
GREAT
|
| Average 1W Daily Value |
0.90 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:25 |
| Symbol | RNAC |
| Name | CARTESIAN THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 29.38 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 227.12 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7495 New Horizon Way, Frederick, MD, United States, 21703
Phone: 301 348 8698
Website: https://www.cartesiantherapeutics.com
Employees: 75
Sector: Healthcare >> Biotechnology
Description: Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google